ADVA
5.5.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s playing a key role in three research and development (R&D) projects building future-proof secure communication networks based on quantum key distribution (QKD). Funded by Germany’s Federal Ministry of Education and Research (BMBF), the initiatives aim to address the significant cybersecurity threat posed by quantum hacking and create the next generation of quantum-safe transport infrastructure with technology made in Germany. In cooperation with other consortium partners, ADVA will accelerate the commercial adoption of QKD technology by making it deployable at scale, robust and easy to integrate.
“The looming threat of large quantum computers puts our most sensitive data at risk. There’s also the immediate danger of cybercriminals harvesting encrypted information now so they can decrypt it when quantum computers become accessible. This is why the switch to quantum-safe encryption is essential for the long-term security of critical data. QKD is based on quantum technology and protects the key exchange between communication endpoints. Even if there is future progress in decryption algorithms and computational capabilities, either classical or quantum, an adversary cannot intercept the keys,” said Michael Roth, GM at Network Security, ADVA. “We understand the requirements of both the quantum and the communication world. By lending our technology and know-how, we’re bridging the gap between them. The BMBF-funded initiatives we’re involved in will make QKD usable for commercial and government customers. Together with our partners, we’re moving this technology to the next level for robust, seamless deployment at scale in today’s optical networks.”
Each of the three projects involves a consortium of industry and research partners with leading expertise in quantum technologies, cryptography, optical communication, and network operation. Coordinated by Deutsche Telekom, the DemoQuanDT project will demonstrate secure quantum key exchange over a fiber optic link between Berlin and Bonn and investigate key management in a multi-vendor environment. Led by Infosim, the QuNet+ML project will research methods for optimizing quantum key distribution in large-scale networks using machine learning. And finally, the DE-QOR project led by ADVA will develop compact and cost-effective continuous-variable QKD (CV-QKD) technology compatible with existing metro and long-distance fiber infrastructure.
“QKD offers a way to achieve true long-term network security today. In just a few years, we’re likely to see current public key cryptosystems rendered obsolete by malicious actors with quantum computers, whether that’s criminal organizations seeking profit or state-sponsored actors aiming to infiltrate critical national infrastructure. It’s therefore crucial that we harness quantum technology quickly in order to stay ahead in the cybersecurity race. Our involvement in these latest BMBF projects is testament to ADVA’s role as a leader in this vital R&D space,” commented Helmut Griesser, director of advanced technology at ADVA. “From day one, our ConnectGuard™ encryption technology has been at the forefront of quantum-safe communication by offering an open, standards-based interface to external QKD systems. Leveraging our expertise in coherent transmission, digital signal processing and cryptography, we’re now working towards our own CV-QKD solution to give customers more choice.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005590/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
